Transgene Biotek Ltd has announced that following the remarkable efficacy displayed by the monoclonal antibody drug developed by its scientists, the company has filed a patent on this novel and unique drug. Even through the company targeted initially to develop a monoclonal antibody based drug for the treatment of colon cancer, subsequent R&D work has proven its efficacy against two other cancers also.
This efficacy, although not unknown in one of two monoclonal antibody-based drugs such as Rixuximab, is unique as being effective against three different cancers - colon cancer. Multiple myeloma and Non-Hodgkin's Lymphoma. There is no other known monoclonal based drug in the world which demonstrated similar therapeutic effect against all these three cancers.
The company is now advancing this mAb for complete humanization in preparation for pre-clinical and clinical studies, a company release said.
The novel platforms, unique in their nature, provide the basis for developing drug with exciting potential for addressing various medical conditions, the conditions hitherto proven to platforms developed and employed by us in the case of AIDS therapeutic vaccine, for example, based on induced highly selective cyto-toxicity, is to treat patients suffering from uniqueness of our AAV/RNAi platform with drugs targeting liver and breast cancers, which is aimed at not only being an effective treatment for these two cancers but also, to be devoid of short or long term effects on the genetic and chromosoma make-up of the recipient patients.
With a robust product pipeline for varying conditions such as AIDS Multiple Sclerosis and six different cancers - each based the company's unique and novel technology platforms. Transgene has now consolidated its development programme in order that necessary thrust and support be provided to reach a targeted objective on each drug at the earliest.